Your browser doesn't support javascript.
loading
Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
Okayama, Taro; Suzuki, Katsuyoshi; Morishita, Shinichiro; Inoue, Junichiro; Tanaka, Takashi; Nakano, Jiro; Fukushima, Takuya.
  • Okayama T; Division of Rehabilitation Medicine, Shizuoka Cancer Center, Shizuoka, Japan.
  • Suzuki K; Division of Rehabilitation Medicine, Shizuoka Cancer Center, Shizuoka, Japan.
  • Morishita S; Department of Physical Therapy, School of Health Science, Fukushima Medical University, Fukushima, Japan.
  • Inoue J; Division of Rehabilitation Medicine, Kobe University Hospital International Clinical Cancer Research Center, Kobe, Japan.
  • Tanaka T; Department of Rehabilitation, Hyogo Medical University Hospital, Nishinomiya, Japan.
  • Nakano J; Faculty of Rehabilitation, Kansai Medical University, Osaka, Japan.
  • Fukushima T; Faculty of Rehabilitation, Kansai Medical University, Osaka, Japan. fukustak@makino.kmu.ac.jp.
BMC Cancer ; 24(1): 495, 2024 Apr 18.
Article en En | MEDLINE | ID: mdl-38637726
ABSTRACT

BACKGROUND:

Although many studies have explored the correlation between quality of life and survival, none have reported this relationship for specific cancers assessed at distinct time points. This meta-analysis aimed to investigate the impact of pretreatment Global Quality of Life (QOL) and functioning QOL, including physical, social, role, emotional, and cognitive QOLs, on mortality risk in patients with lung cancer.

METHODS:

A literature search was conducted across the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and PubMed databases for articles published between their inception and December 2022. Subsequently, 11 studies were selected based on predefined eligibility criteria to investigate the relationship between pretreatment QOLs and mortality risk in patients with lung cancer.

RESULTS:

Pretreatment global, physical, social, role, and emotional QOLs were significantly associated with mortality risk as follows Global QOL (hazard ratio [HR] = 1.08 95% confidence interval [CI] = 1.03-1.13); Physical QOL (HR = 1.04 95% CI = 1.02-1.05); Social QOL (HR = 1.02 95% CI = 1.01-1.03; Role QOL (HR = 1.01 95% CI = 1.01-1.02); Emotional QOL (HR = 1.01 95% CI = 1.00-1.03).

CONCLUSIONS:

These findings underscore the importance of early QOL assessment after diagnosis as well as early provision of physical, social, and psychological support accommodating each patient's demands. TRIAL REGISTRATION The International Prospective Register of Systematic Reviews registration number CRD42023398206, Registered on February 20, 2023.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pulmonares Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pulmonares Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article